Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $44.25

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.25.

Several equities research analysts have recently commented on STOK shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price target for the company. Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on Stoke Therapeutics in a research report on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 4,767 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the completion of the sale, the insider owned 25,655 shares of the company’s stock, valued at approximately $821,729.65. The trade was a 15.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel owned 21,225 shares in the company, valued at $679,836.75. This represents a 11.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 28,828 shares of company stock valued at $898,874 in the last three months. Corporate insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in STOK. BlackRock Inc. acquired a new position in shares of Stoke Therapeutics during the 2nd quarter worth $192,307,000. RTW Investments LP lifted its stake in shares of Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after purchasing an additional 423,331 shares during the last quarter. Redmile Group LLC boosted its holdings in Stoke Therapeutics by 3.2% in the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock worth $135,584,000 after purchasing an additional 130,050 shares in the last quarter. Morgan Stanley boosted its holdings in Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after purchasing an additional 9,108 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Stoke Therapeutics by 13.7% in the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock worth $115,152,000 after purchasing an additional 423,601 shares in the last quarter.

Stoke Therapeutics Trading Down 1.3%

Shares of NASDAQ STOK opened at $31.20 on Friday. Stoke Therapeutics has a twelve month low of $18.80 and a twelve month high of $40.22. The firm has a 50-day moving average of $31.23 and a two-hundred day moving average of $32.25. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -9.34 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The business had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. As a group, research analysts predict that Stoke Therapeutics will post -3.52 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.